alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2024-1 Phase I: Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune—Mediated Diseases (Topic 135).                    

*Date:*                         February 21, 2024.                    

*Time:*                         9:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21A, Rockville, MD 20892 (Video Assisted Meeting).                    

*Contact Person:*                         Shiv A. Prasad, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G21A, Rockville, MD 20892,                         *shiv.prasad@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 22, 2024.

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-01564 Filed 1-25-24; 8:45 am]

BILLING CODE 4140-01-P
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0001013148
<NAME> XYBERNAUT CORPORATION
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           2,031
<SECURITIES>                                         0
<RECEIVABLES>                                      848
<ALLOWANCES>                                       141
<INVENTORY>                                      6,060
<CURRENT-ASSETS>                                 9,355
<PP&E>                                           2,072
<DEPRECIATION>                                   1,376
<TOTAL-ASSETS>                                  11,323
<CURRENT-LIABILITIES>                            7,920
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      3,997
<COMMON>                                           299
<OTHER-SE>                                       (893)
<TOTAL-LIABILITY-AND-EQUITY>                    11,323
<SALES>                                          3,302
<TOTAL-REVENUES>                                 3,340
<CGS>                                            2,854
<TOTAL-COSTS>                                    2,854
<OTHER-EXPENSES>                                17,310
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  78
<INCOME-PRETAX>                               (16,747)
<INCOME-TAX>                                        29
<INCOME-CONTINUING>                           (16,776)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (16,776)
<EPS-BASIC>                                     (0.78)
<EPS-DILUTED>                                   (0.78)


</TABLE>
[Federal Register Volume 89, Number 22 (Thursday, February 1, 2024)]
[Notices]
[Page 6523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02038]


=======================================================================
-----------------------------------------------------------------------

FEDERAL ELECTION COMMISSION


Sunshine Act Meetings

TIME AND DATE: Tuesday, February 6, 2024 at 10:00 a.m. and its 
continuation at the conclusion of the open meeting on February 8, 2024.

PLACE: 1050 First Street NE, Washington, DC and virtual (this meeting 
will be a hybrid meeting).

STATUS: This meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Compliance matters pursuant to 52 U.S.C. 
30109.
    Matters relating to internal personnel decisions, or internal rules 
and practices.
    Information the premature disclosure of which would be likely to 
have a considerable adverse effect on the implementation of a proposed 
Commission action.
    Matters concerning participation in civil actions or proceedings or 
arbitration.

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer, 
Telephone: (202) 694-1220.
* * * * *
(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Vicktoria J. Allen,
Deputy Secretary of the Commission.
[FR Doc. 2024-02038 Filed 1-29-24; 4:15 pm]
BILLING CODE 6715-01-P
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 06-7149
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus ANTHONY ALLEN QUINN, Defendant - Appellant. Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Leonie M. Brinkema, District Judge. (1:01-cr-00089) Submitted: November 6, 2006 Decided: November 20, 2006 Before MOTZ and SHEDD, Circuit Judges, and HAMILTON, Senior Circuit Judge. Affirmed by unpublished per curiam opinion. Anthony Allen Quinn, Appellant Pro Se. William Neil Hammerstrom, Jr., OFFICE OF THE UNITED STATES ATTORNEY, Alexandria, Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).- 2 - PER CURIAM: Anthony Allen Quinn appeals a district court order denying his motion for sentence reduction pursuant to Fed. R. Crim. P. 35(b). We have reviewed the record and the district court opinion and affirm for the reasons cited by the district court. See United States v. Quinn , No. 1:01-cr-00089 (E.D. Va. June 9, 2006). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
**Exhibit
      32.2**





**Certification
      of Principal Financial Officer Regarding Periodic Report Containing Financial**


**Statements
      pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the
      Sarbanes-**


**Oxley
      Act of 2002**





I,
      Bruce
      W. Elder, the Principal Financial Officer of Crescent Financial Corporation,
      in
      compliance with 18 U.S.C Section 1350, as adopted pursuant to Section 906 of
      the
      Sarbanes-Oxley Act of 2002, hereby certify that, (i) the Form 10-Q filed by
      Crescent Financial Corporation (the "Issuer") for the quarter ended June 30,
      2007, fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934, and (ii) the information contained in that
      report fairly presents, in all material respects, the financial condition and
      results of operations of the Issuer on the dates and for the periods presented
      therein.




Date: August
                8, 2007
            By:
            /s/ Bruce
                W.
                ElderBruce
                      W. Elder
                    Principal
                      Financial Officer
Exhibit
32




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO




SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly report
of Megola, Inc. (the "Company") on Form 10-Q for the period ending April 30,
2008, as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Joel Gardner, acting in the capacity as thePresident, CEO, Principal
Financial Officer and Principal Accounting Officer of the Company, certify to the best of my knowledge,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:




(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and




(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and result of operations of the Company.




/s/ Joel
      GardnerJoel
      GardnerPresident,
      CEO, Principal FinancialOfficer and Principal Accounting
OfficerApril
      2, 2009
**Exhibit 31.2**

 

CERTIFICATION

 

I, Thomas R. Moyes, Chief Financial Officer ofMediCor Ltd. (the “Registrant”), certify that:

 

1.             I have reviewed this Quarterly Report on Form 10-QSBof the Registrant;

 

2.             Based on my knowledge, this report does notcontain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3.             Based on my knowledge, the financialstatements, and other financial information included in this report, fairlypresent in all material respects the financial condition, results of operationsand cash flows of the Registrant as of, and for, the periods presented in thisreport;

 

4.             The Registrant’s other certifying officersand I are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))for the Registrant and have:

 

(a)     Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the Registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

 

(b)     Evaluated the effectiveness of the Registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectivenessof the disclosure controls and procedures, as of the end of the period coveredby this report based on such evaluation; and

 

(c)     Disclosed in this report any change in the Registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the Registrant’s fourth fiscal quarter in the case ofthis annual report) that has materially affected, or is likely to materiallyaffect, the Registrant’s internal control over financial reporting; and

 

5.             The Registrant’s other certifying officersand I have disclosed, based on our most recent evaluation of internal controlover financial reporting, to the Registrant’s auditors and the audit committeeof Registrant’s board of directors (or persons performing the equivalentfunctions):

 

(a)     All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonablylikely to adversely affect the Registrant’s ability to record, process,summarize and report financial information; and

 

(b)     Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the Registrant’s internal control overfinancial reporting.

 

 
| Dated: February 6, 2006  |
|-------------------------------|
|                          |
| /s/ Thomas R. Moyes           |   |
| Thomas R. Moyes,              |
| Chief Financial Officer       |
| (Principal Financial Officer) |

 

----
**Exhibit 32.2**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF2002**

 

The undersigned, the Chief Financial Officer of Gladstone CapitalCorporation (the “Company”), hereby certifies on the date hereof, pursuant to18 U.S.C. §1350(a), as adopted pursuant to Section 906 of TheSarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for thequarter ended December 31, 2008 (“Form 10-Q”), filed concurrentlyherewith by the Company, fully complies with the requirements of Section 13(a) orSection 15(d) of the Securities Exchange Act of 1934, as amended, andthat the information contained in the Form 10-Q fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 

Dated: February 3,2009

 

 
| /s/ Gresford Gray       |   |
|-------------------------|--------|
| Gresford Gray           |
| Chief Financial Officer |

 

----
#### David L. TRODGLEN, Petitioner, v. Dan M. GRIFFITH, Judge, Daviess Circuit Court, Respondent.

Court of Appeals of Kentucky.

Nov. 22, 1963.

David L. Trodglen, pro se.

CLAY, Commissioner.

This is an original proceeding seeking to compel the Judge of the Daviess Circuit Court to send up the record on appeal from a judgment of conviction entered sometime in January, 1963. The petitioner proceeds in forma pauperis.

*796The petition fails to show the date of the judgment and fails to show that the notice of appeal was filed within the time required by CrR 12.54. Assuming the notice of appeal was timely filed, the period within which the petitioner could file the record on appeal in this Court under CrR 12.58 has long since expired.

There are other deficiencies in the petition and it does not state sufficient facts to show any right to effective relief. A party, even though not represented by counsel, must'comply with applicable procedural rules when proceeding by way of appeal' or by original action in this Court. We' cannot grant relief simply because such party files miscellaneous papers in this Court.

On the record before us we find nothing to justify our issuance of a mandamus order, and the prayer of the petition is denied.
**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the Quarterly Report of GlobeTrac Inc. (“GlobeTrac”) on Form
      10-QSB for the period ending June 30, 2005 as filed with the Securities and
      Exchange Commission on the date hereof (the “Report”), I, Jim Pratt, President,
      Chief Executive Officer of GlobeTrac and a member of the Board of Directors,
      certify, pursuant to s.906 of the Sarbanes-Oxley Act of 2002, that:




(1)
        The Report fully complies with the requirements of section 13(a) or
      15(d)
      of the Securities Exchange Act of 1934; and




(2)
        The information contained in the Report fairly represents, the financial
      condition and result of operations of GlobeTrac.








*/s/
      Jim Pratt*


Jim
      Pratt


Chief
      Executive Officer


August
      12, 2005











**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the Quarterly Report of GlobeTrac Inc. (“GlobeTrac”) on Form
      10-QSB for the period ending June 30, 2005 as filed with the Securities and
      Exchange Commission on the date hereof (the “Report”), I, John daCosta,
      Secretary, Treasurer, and Chief Financial Officer of GlobeTrac, certify,
      pursuant to s.906 of the Sarbanes-Oxley Act of 2002, that:




(1)
        The Report fully complies with the requirements of section 13(a) or
      15(d)
      of the Securities Exchange Act of 1934; and




(2)
        The information contained in the Report fairly represents, the financial
      condition and result of operations of GlobeTrac.






*/s/
      John daCosta*


John
      daCosta


Chief
      Financial Officer


August
      12, 2005
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF POST APARTMENT HOMES, L.P. FOR THE PERIOD ENDED DECEMBER
31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<RESTATED>
<CIK> 0001012271
<NAME> POST APARTMENT HOMES, L.P.

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       1,381,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                   1,109,342,000
<DEPRECIATION>                             177,672,000
<TOTAL-ASSETS>                             958,675,000
<CURRENT-LIABILITIES>                                0
<BONDS>                                    434,319,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                 482,434,000
<TOTAL-LIABILITY-AND-EQUITY>               958,675,000
<SALES>                                              0
<TOTAL-REVENUES>                           170,708,000
<CGS>                                                0
<TOTAL-COSTS>                               85,983,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          22,131,000
<INCOME-PRETAX>                             52,599,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         52,390,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                52,390,000
<EPS-PRIMARY>                                     1.95<F1>
<EPS-DILUTED>                                     1.94
<FN>
<F1>REPRESENTS BASIC EARNINGS PER SHARE
</FN>


</TABLE>
<PAGE>   1
                                                                    EXHIBIT 23.2


INDEPENDENT AUDITORS' CONSENT


We consent to the incorporation by reference in the Registration Statement of
SRS Labs, Inc. pertaining to SRS Labs, Inc. 1996 Nonemployee Directors Stock
Option Plan on Form S-8 of our report dated May 10, 1996 (except for information
pertaining to the reverse stock split and reincorporation described in Note 1 as
to which the date is June 28, 1996), appearing in the Company's Prospectus dated
August 8, 1996, filed with the Commission on August 12, 1996, pursuant to Rule
424(b).


/s/ Deloitte & Touche LLP

Costa Mesa, California
December 30, 1996
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 1997 AND THE CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 1997 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                              92
<SECURITIES>                                     2,528
<RECEIVABLES>                                    4,476
<ALLOWANCES>                                       369
<INVENTORY>                                      3,742
<CURRENT-ASSETS>                                11,128
<PP&E>                                           7,785
<DEPRECIATION>                                   1,550
<TOTAL-ASSETS>                                  23,059
<CURRENT-LIABILITIES>                           12,224
<BONDS>                                          4,205
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        12,238
<OTHER-SE>                                     (5,608)
<TOTAL-LIABILITY-AND-EQUITY>                    23,059
<SALES>                                         30,386
<TOTAL-REVENUES>                                30,386
<CGS>                                           22,146
<TOTAL-COSTS>                                   36,002
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 603
<INCOME-PRETAX>                                (6,124)
<INCOME-TAX>                                       230
<INCOME-CONTINUING>                            (5,894)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,894)
<EPS-PRIMARY>                                   (1.35)
<EPS-DILUTED>                                   (1.35)


</TABLE>
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of In Vivo Medical Diagnostics, Inc.
(the "Company") on Form 10-QSB for the quarter ended January 31, 2005 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, In Vivo Medical Diagnostics, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

A signed original of this written statement required by Section 906 has been
provided to In Vivo Medical Diagnostics, Inc. and will be retained by In Vivo
Medical Diagnostics, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.







March 22, 2005                                       /s/ Bernard Turner
                                                     ---------------------------
                                                     Bernard Turner
                                                     Chief Financial Officer